Published in Proc Natl Acad Sci U S A on July 15, 1991
Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 4.80
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol (1992) 2.83
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A (1994) 2.49
Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol (1995) 2.45
BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol (1991) 2.28
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J Virol (1992) 1.91
Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci U S A (1995) 1.89
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol (1993) 1.88
Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J (1996) 1.80
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer (1996) 1.70
Transcription of the Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells. J Virol (1992) 1.66
The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J Virol (1992) 1.61
Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol (1993) 1.55
Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol (1992) 1.55
Constitutive binding of EBNA1 protein to the Epstein-Barr virus replication origin, oriP, with distortion of DNA structure during latent infection. EMBO J (1993) 1.53
Structural analyses of the Epstein-Barr virus BamHI A transcripts. J Virol (1995) 1.49
Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol (1995) 1.43
Detection and characterization of Epstein-Barr virus in clinical specimens. Am J Pathol (1994) 1.34
Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol (1993) 1.31
Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. J Virol (1992) 1.30
EBNA-1, the major nuclear antigen of Epstein-Barr virus, resembles 'RGG' RNA binding proteins. EMBO J (1994) 1.29
Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol (1997) 1.28
Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J Virol (1996) 1.27
The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines. J Virol (1995) 1.24
Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency. J Virol (1999) 1.23
Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants. J Virol (1992) 1.18
Molecular genetic analysis of Epstein-Barr virus Cp promoter function. J Virol (1996) 1.16
Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor. Mol Cell Biol (1994) 1.14
Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates. J Virol (1999) 1.13
The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol (2000) 1.12
The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol (1998) 1.06
A simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycle. J Virol (1996) 1.03
Host-cell-phenotype-dependent control of the BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proc Natl Acad Sci U S A (1992) 1.03
The role of EBV in post-transplant malignancies: a review. J Clin Pathol (2000) 1.02
Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J Cancer Res Clin Oncol (2005) 1.02
Identification of spliced gammaherpesvirus 68 LANA and v-cyclin transcripts and analysis of their expression in vivo during latent infection. J Virol (2006) 1.01
Reciprocal antagonism of steroid hormones and BZLF1 in switch between Epstein-Barr virus latent and productive cycle gene expression. J Virol (1992) 0.99
Host factors LR1 and Sp1 regulate the Fp promoter of Epstein-Barr virus. Proc Natl Acad Sci U S A (1995) 0.97
The cellular proteins that bind specifically to the Epstein-Barr virus origin of plasmid DNA replication belong to a gene family. Proc Natl Acad Sci U S A (1994) 0.94
The Epstein-Barr virus EBNA-1 promoter Qp requires an initiator-like element. J Virol (1997) 0.93
Establishment and characterization of a human Epstein-Barr virus-associated gastric carcinoma in SCID mice. J Virol (1998) 0.93
Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J Clin Pathol (1996) 0.92
Epstein-Barr virus-induced epigenetic alterations following transient infection. Int J Cancer (2012) 0.92
The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer (2001) 0.90
Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions. J Virol (1992) 0.89
Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature. J Virol (2012) 0.89
Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus. J Virol (2001) 0.89
Expression of Epstein-Barr virus encoded latent genes in nasal T cell lymphomas. J Clin Pathol (1996) 0.84
Regulation of the double-stranded RNA-dependent protein kinase PKR by RNAs encoded by a repeated sequence in the Epstein-Barr virus genome. Nucleic Acids Res (1996) 0.84
Asymmetric Arginine dimethylation of Epstein-Barr virus nuclear antigen 2 promotes DNA targeting. Virology (2009) 0.84
Nucleic acid sequence-based amplification, a new method for analysis of spliced and unspliced Epstein-Barr virus latent transcripts, and its comparison with reverse transcriptase PCR. J Clin Microbiol (1998) 0.83
Expression of Epstein-Barr Virus Gene and Clonality of Infiltrated T Lymphocytes in Epstein-Barr Virus-associated Gastric Carcinoma. Immune Netw (2011) 0.81
Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein-Barr virus associated disorders. Mol Pathol (2001) 0.79
Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas. World J Gastroenterol (2015) 0.76
Dual EBNA1 promoter usage by Epstein-Barr virus in human B-cell lines expressing unique intermediate cellular phenotypes. J Virol (1994) 0.76
Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma. Front Microbiol (2017) 0.75
Latent Epstein-Barr virus infection in cottontop tamarins. A possible model for Epstein-Barr virus infection in humans. Am J Pathol (1994) 0.75
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 14.39
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A (1986) 5.12
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. J Virol (1987) 3.58
Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol (1990) 3.51
Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci U S A (1990) 3.29
Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells. J Virol (1982) 3.26
A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol (1987) 3.10
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol (1991) 3.03
EBV gene expression in an NPC-related tumour. EMBO J (1989) 2.94
A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol (1990) 2.60
An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J Exp Med (1990) 2.44
Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J Virol (1989) 2.36
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol (1989) 1.99
An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol (1990) 1.79
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A (1990) 1.74
Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes. J Virol (1990) 1.74
Epstein-Barr virus transcription in nasopharyngeal carcinoma. J Virol (1983) 1.57
Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol (1988) 1.37
Expression of EBNA-3 family in fresh B lymphocytes infected with Epstein-Barr virus. Virology (1989) 1.06
The metabolism of naphthalene in rabbits. Biochem J (1934) 31.93
Synthesis of l-alpha-naphthylmercapturic acid. Biochem J (1934) 12.42
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Sulfonamide resistance gene for plant transformation. Plant Mol Biol (1990) 6.28
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
Genetic control of programmed cell death in Drosophila. Science (1994) 6.08
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A (1993) 5.92
Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol (1984) 5.87
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci U S A (1984) 5.60
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol (1980) 5.59
Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science (1996) 5.55
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A (1986) 5.12
Genetic relatedness of type 1 and type 2 herpes simplex viruses. J Virol (1972) 5.11
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci U S A (1983) 4.94
Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line. Proc Natl Acad Sci U S A (1981) 4.77
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol (1988) 4.55
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol (1981) 4.38
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell (1980) 4.14
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. Science (1983) 4.04
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A (1994) 3.88
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell (1987) 3.87
Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol (1976) 3.83
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A (1993) 3.66
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol (1986) 3.65
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. J Virol (1987) 3.58
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol (1990) 3.51
DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus. J Virol (1978) 3.41
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Body Composition: Studies in the Human Being by the Dilution Principle. Science (1952) 3.27
A second nuclear protein is encoded by Epstein-Barr virus in latent infection. Science (1985) 3.26
Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells. J Virol (1982) 3.26
Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol (1991) 3.24
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (1996) 3.22
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J Virol (1993) 3.19
Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci U S A (1991) 3.17
Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol (1989) 3.09
The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene (1995) 3.07
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J Virol (1983) 3.06
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol (2001) 2.99
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription. J Biol Chem (1997) 2.93
Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection. J Virol (1979) 2.90
Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem (1996) 2.85
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 2.81
Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA. Science (1984) 2.77
DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus. J Virol (1978) 2.76
The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol (1988) 2.74
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity (1995) 2.74
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol (1995) 2.71
Epstein-Barr virus DNA XII. A variable region of the Epstein-Barr virus genome is included in the P3HR-1 deletion. J Virol (1982) 2.70
DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol (1979) 2.63
Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci U S A (1986) 2.62
Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl Acad Sci U S A (1983) 2.61
A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol (1990) 2.60
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity. Int J Cancer (1982) 2.55
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology (1987) 2.53
Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections. J Virol (1982) 2.51
NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A (2000) 2.48
Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell (1994) 2.48
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med (1994) 2.47